| March 2007 · Vol. 19, No. 03 UPDATE
NEW DEVELOPMENTS THAT ARE CHANGING PATIENT CARE
CERVICAL DISEASE
The HPV vaccine is a boon to prevention efforts, but other aspects of cervical cancer screening and treatment still require our attention
|
Fast Track
Current, former, and never users of OCs all had the same risk of being HPV-positive
All types of excisional procedures produce similar pregnancy-related morbidities
When only high-quality studies are analyzed, liquid-based cytology does not appear to increase detection of HSIL
Liquid-based cytology has no greater sensitivity than conventional cytology
|
|
Thomas
C.
Wright,
MDProfessor of Pathology, Columbia University, New York City Chair, 2006 Consensus Conference, American Society for Colposcopy and Cervical Pathology
Dr. Wright is an author of the 2001 Consensus Guidelines on Managing Women with Cytological and Histological Abnormalities, the 2004 Interim Guidance for Use of HPV DNA Testing for Primary Screening, and the 2001 Bethesda System
The year 2006 was a busy one for those of us engaged in cervical cancer prevention. The most notable development was approval by the US Food and Drug Administration of the human papillomavirus (HPV) quadrivalent vaccine in June, followed closely by guidelines for its use from the Advisory Committee on Immunization Practices (June) and the American College of Obstetricians and Gynecologists (September). Key issues related to the introduction of the HPV vaccine into clinical practice were reviewed in a roundtable discussion in the January 2007 issue of OBG Management.
Therefore, this update will depart, for the moment, from matters related to the vaccine and concentrate on several other critical areas:
|
